Researchers Develop Genetic Test To Help Identify Patients With Cancer At Highest Risk For Complication From Treatment With Bevacizumab

Medscape (10/30, Osterweil, Subscription Publication) reported, “Up to 40% of patients with cancer who are treated with bevacizumab develop severe hypertension and renal toxicity,” but researchers have developed a “genetic test performed before treatment” that “could identify patients at highest risk for this potentially life-threatening complication.” The findings were presented “in a plenary session during the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.”